Today: 2 July 2026
Texas Instruments stock (TXN) heads into earnings week after Friday dip — what to watch next
25 January 2026
1 min read

Texas Instruments stock (TXN) heads into earnings week after Friday dip — what to watch next

New York, Jan 25, 2026, 16:13 EST — Market closed.

  • Texas Instruments Incorporated shares fell 0.9%, ending Friday at $193.31.
  • A Stifel analyst kept a Hold rating ahead of the company’s earnings report due Jan. 27.
  • Investors are focusing on the demand and margin outlook as the dividend record date approaches on Jan. 30.

Shares of Texas Instruments Incorporated edged down 0.9% to $193.31 on Friday, with investors cautious ahead of a packed earnings slate for U.S. chipmakers.

Since the market is closed Sunday, attention shifts to Tuesday for the next real test of TXN. Texas Instruments serves as a key gauge for demand in factories and autos—sectors notorious for slow changes that can heavily strain margins when they weaken.

This is crucial now, with investors hunting for clear signals that orders are either holding steady or just shifting around, while companies rush to trim inventories. Production also adds pressure: chip fabs operating below capacity can seriously dent profits, even if sales stay flat.

Stifel’s Tore Svanberg kept a Hold rating and a $200 price target on Friday, pointing to tariff uncertainty and near-term margin pressures despite expecting broader improvements down the line. He said, “While the analog market appears to be turning the corner, choppy 1H26 macro dynamics and tariff uncertainty lead us to remain conservative.” StreetInsider.com

Svanberg said he expects results to come in roughly on target but flagged “tactical under-loading” as a near-term headwind. Under-loading means running factories below full capacity, which spreads fixed costs over fewer chips and squeezes gross margins.

Traders are zeroing in on any changes in sentiment about industrial and automotive demand, particularly if customers are submitting new orders or just pulling forward ones already on the books. The March quarter guidance is expected to dominate the narrative.

Texas Instruments said it will webcast its Q4 and full-year 2025 earnings call on Tuesday, Jan. 27, at 3:30 p.m. Central. CEO Haviv Ilan and CFO Rafael Lizardi will head the call.

The company declared a quarterly cash dividend of $1.42 per share, payable on Feb. 10, 2026, to shareholders on record as of Jan. 30.

Over the weekend, the analog sector painted a mixed picture. Analog Devices fell about 1%, while NXP Semiconductors slid nearly 1.8%. Attention now shifts to Texas Instruments, which investors hope will help stabilize the group.

The risk is evident. If Texas Instruments offers cautious March-quarter revenue guidance or signals that factory utilization is still low, investors may quickly cut earnings estimates. This comes amid persistent worries over tariffs and slower macroeconomic growth hitting customer demand.

Tuesday brings the next major update, as the company is set to drop its earnings report after the market shuts. The announcement will be followed by a call for investors.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings
Next Story

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings

Go toTop